Sets New Benchmark for Transparency and Compliance in Clinical Trial Management
Chicago, IL - ArisGlobal, a leading provider of integrated, cloud-based software solutions for life sciences, announces agClinical 3.3, the latest version of its comprehensive clinical trial management software. This release further enables life science organizations to confidently and efficiently meet new compliance and submission requirements, improve risk-based monitoring and better manage the electronic trial master file so that compliance is assured and transparency is improved.
"We benefit from a collaborative relationship with our customers, and we have taken their valued, best-practices input and added new functionality to our already comprehensive solution to position our customers for success," said David Laky, ArisGlobal's General Manager and VP, Clinical Development. "We are confident that agClinical 3.3 responds to their need for reducing the labor-intensive aspects of clinical trial management."
agClinical 3.3 includes:
"Clinical trials are highly regulated, complex undertakings," said Sonia Veluchamy, ArisGlobal Managing Director. "agClinical is recognized by customers and analysts as one of the most functionally-rich CTMS solutions on the market. This newest version further solidifies our position as the leader in this splintered market."
About ArisGlobal
ArisGlobal's cloud-based solutions facilitate global drug development and regulatory compliance in the life sciences and healthcare industries across the entire product life cycle including clinical development, regulatory affairs, safety and pharmacovigilance and medical communications. Hundreds of drug and device manufacturers, CROs and regulatory agencies leverage ArisGlobal's advanced technology solutions spanning regulatory information management, pharmacovigilance regulatory reporting, medical information and clinical trial management software to make better and more informed decisions, facilitate compliance, reduce risk, and improve operational efficiency. Headquartered in the United States, ArisGlobal has regional offices in Europe, India and Japan. For more information, visit arisglobal.com, or follow ArisGlobal on LinkedIn and Twitter.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.